Skip to product information
1 of 1

SLU-PP-332

SLU-PP-332

Regular price £45.00
Regular price Sale price £45.00
Sale Sold out
Taxes included. Shipping calculated at checkout.

Multi-buy savings: save 4% on 2+ items and 6% on 3+. Applied automatically in your cart.

Size

Quantity

Email me when it's back

Leave your email and we'll let you know when this size is back in stock.

You'll also get our occasional email updates. Unsubscribe at any time.
  • Same-day dispatch on orders before 2pm, Royal Mail Tracked
  • Free UK shipping on orders over £100
  • Certificate of Analysis with every order · Request CoA
  • For in vitro laboratory research use only
Concentration calculator
Concentration–
Molarity–

For laboratory calculation only. Not for human or veterinary use.

SLU-PP-332 is a potent pan-agonist of the estrogen-related receptor (ERR) family — ERRα, ERRβ, and ERRγ — developed at St Louis University as a selective chemical probe for ERR-mediated transcriptional programmes. It functions as an exercise mimetic by activating the same mitochondrial biogenesis and oxidative metabolism pathways induced by physical exercise, without requiring physical activity.

Mechanistically, SLU-PP-332 drives ERR-dependent transcription of genes involved in fatty acid oxidation, OXPHOS complex assembly, and mitochondrial fusion dynamics. In rodent studies, it has been shown to increase aerobic exercise capacity and activate skeletal muscle fibre type switching. Its selectivity for ERRα/β/γ over classical oestrogen receptors (ERα/β) makes it a valuable tool for dissecting ERR-specific biology.

Research areas

  • ERRα/β/γ agonism
  • Mitochondrial biogenesis
  • Oxidative metabolism
  • Exercise mimetic pharmacology
  • Skeletal muscle biology
  • AMPK / OXPHOS signalling

PubChem CID: 5338394 · Formula: C18H14N2O2 · MW: 294.3 g/mol · Purity: ≥99% HPLC · Format: Lyophilised powder · Storage: −20 °C.

Research Use Only. Supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary administration. Not evaluated by the MHRA or FDA for therapeutic use. Researchers must comply with the Human Medicines Regulations 2012 and all applicable institutional guidelines. Peptide Biosciences accepts no liability for use outside a controlled research context.

View full details